Disruption of sleep architecture in *Prevotella* enterotype of patients with obstructive sleep apnea-hypopnea syndrome

Chih-Yuan Ko1,2,3,4* | Ji-Mim Fan1,2,3* | An-Ke Hu1,2,3* | Huan-Zhang Su1,2,3
Jiao-Hong Yang1,2,3 | Li-Mei Huang1,2,3 | Fu-Rong Yan1,2,3,5 | Hua-Ping Zhang1,2,3
Yi-Ming Zeng1,2,3

**Abstract**

**Introduction:** Intermittent hypoxia and sleep fragmentation are critical pathophysiological processes involved in obstructive sleep apnea-hypopnea syndrome (OSAHS). Those manifestations independently affect similar brain regions and contribute to OSAHS-related comorbidities that are known to be related to the host gut alteration microbiota. We hypothesized that gut microbiota disruption may cross talk the brain function via the microbiota–gut–brain axis. Thus, we aim to survey enterotypes and polysomnographic data of patients with OSAHS.

**Methods:** Subjects were diagnosed by polysomnography, from whom fecal samples were obtained and analyzed for the microbiome composition by variable regions 3–4 of 16S rRNA pyrosequencing and bioinformatic analyses. We examined the fasting levels of interleukin-6 and tumor necrosis factor-alpha of all subjects.

**Results:** Three enterotypes *Bacteroides*, *Ruminococcus*, and *Prevotella* were identified in patients with OSAHS. Arousal-related parameters or sleep stages are significantly disrupted in apnea-hypopnea index (AHI) ≥15 patients with *Prevotella* enterotype; further analysis this enterotype subjects, obstructive, central, and mixed apnea indices, and mean heart rate are also significantly elevated in AHI ≥15 patients. However, blood cytokines levels of all subjects were not significantly different.

**Conclusions:** This study indicates the possibility of pathophysiological interplay between enterotypes and sleep structure disruption in sleep apnea through a microbiota–gut–brain axis and offers some new insight toward the pathogenesis of OSAHS.

**KEYWORDS**

enterotypes, microbiota, obstructive sleep apnea-hypopnea syndrome, polysomnography, *Prevotella*

---

**Abbreviations:** AHI, apnea-hypopnea index; BMI, body mass index; BP, blood pressure; CNS, central nervous system; CompSAS, complex sleep apnea syndromes; CPAP, continuous positive airway pressure; CSA, central sleep apnea; IBD, inflammatory bowel disease; IH, intermittent hypoxia; IL-6, interleukin-6; LPS, lipopolysaccharide; MAD, apnea-hypopnea duration; MSA, mixed sleep apnea; NREM, non-rapid eye movement; OSAHS, obstructive sleep apnea-hypopnea syndrome; PCA, principal component analysis; PSG, polysomnography; REM, rapid eye movement; SAS, sleep apnea syndromes; SF, sleep fragmentation; TNF-α, tumor necrosis factor alpha.

*These authors have contributed equally to this work.

Ko, Zeng, and Zhang are co-corresponding authors, have contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. *Brain and Behavior* published by Wiley Periodicals, Inc.
1 | INTRODUCTION

Intermittent hypoxia (IH) and sleep fragmentation (SF) are the hallmarks of obstructive sleep apnea-hypopnea syndrome (OSAHS) (Moreno-Indias et al., 2015, 2016; Poroyko et al., 2016). IH plays a critical pathophysiological role in OSAHS, often accompanied by reduced oxygen saturation, increased systemic pressure and bloodstream, excessive sympathetic neural activity, impairment of autonomic function, and apnea episodes end with an arousal of the central nervous system (CNS), ultimately resulting in vascular endothelial dysfunction and multi-organ morbidity consequences. The underlying mechanism involves inflammation and oxidative stress cascades (Gaspar, Álvaro, Moita, & Cavadas, 2017; Lavie, 2015).

Contrastingly, sleep structure disruption is another risk factor for the pathophysiology of OSAHS, causing major end-organ morbidity independent of IH (Rosenzweig, Williams, & Morrell, 2013, 2014). Repeated arousals disturbing different stages of sleep are the predominant mechanism underlying OSAHS-induced brain injury wherein results from disruptions of rapid eye movement (REM) and non-REM (NREM) (Rosenzweig, Williams, & Morrell, 2014). SF promotes obesity and metabolic abnormalities and may be mediated by concurrent alterations of the host gut microbiota and concurrent systemic and adipose tissue inflammatory alterations accompanied by insulin resistance (Farré, Farré, & Gozal, 2018; Poroyko et al., 2016). Reportedly, prolongation of the N1 stage and shortening of REM times were observed in OSAHS-induced hypertensive patients; prolongation of the N1 sleep stage also causes elevation of fasting blood glucose (Shao et al., 2018). Elevated serum lipoplyascharide (LPS)-binding protein levels might prolong the N1 stage and increase SF, which may be related to increased nighttime respiratory events and arousals (Shao et al., 2018). Interestingly, disturbances in sleep continuity are associated with emotional disorders (Palagini, Baglioni, Ciapparelli, Gemignani, & Riemann, 2013); additionally, the disturbance of sleep structure also contributes to mild cognitive decline in OSAHS (Rosenzweig et al., 2014). However, treating OSAHS patients with continuous positive airway pressure (CPAP) has protective effects on neurocognition, postulated that the microbiota could be modulated during CPAP treatment (Xu et al., 2017), implying that the microbiota might participate in the pathophysiological developed mechanism.

Emerging evidence suggests that the gut microbiota plays a crucial role in modulating the risk of several chronic diseases and maintaining intestinal immunity and whole body homeostasis. These effects have important implications for diseases such as obesity, cardiometabolic abnormalities, inflammatory bowel disease (IBD), and mental illness (Singh et al., 2017). Additionally, the gut microbiota alterations manifested in IH and SF mimic in OSAHS animal models (Moreno-Indias et al., 2015; Poroyko et al., 2016). However, some of the underlying mechanisms of OSAHS-related comorbidities remain unclear. Enterotype analysis has been proposed as a useful method to understand human gut microbial communities, including Bacteroides, Ruminococcus, and Prevotella enterotypes, irrespective of ethnicity, gender, age, or body mass index (BMI) (Arumugam et al., 2011). Moreover, enterotypes subdivision provides an attractive framework for linking human disease. For example, Bacteroides enterotype has been reported to pose an increased risk for IBD (Conlon & Bird, 2015; Costea et al., 2018; Knights et al., 2014).

Notably, characteristics of IH and SF in OSAHS can trigger the inflammatory response, which then alters the intestinal microbial community composition (Moreno-Indias et al., 2015; Palagini et al., 2013; Poroyko et al., 2016). Conversely, gut microbiomes can also respond to the brain via the microbiota–gut–brain axis, as has been declared in psychiatric disorders (Sherwin, Sandhu, Dinan, & Cryan, 2016). However, this hypothesis has not been verified for OSAHS. Thus, this study investigated the hypothesis that the microbiota–gut–brain axis is associated with the pathogenesis of OSAHS. We examined whether impaired sleep architecture is associated with gut microbiota alteration by investigating sleep parameters of polysomnography (PSG) data and pro-inflammatory cytokines in various enterotypes of OSAHS subjects.

2 | MATERIALS AND METHODS

2.1 | Subjects

In total, 113 subjects were recruited from July 2017 to January 2018, who were clinically suspicious with OSAHS and committed to sleep examination for the first time at sleep laboratory of Department of Pulmonary and Critical Care Medicine of the Second Affiliated Hospital of Fujian Medical University. Subjects with gastrointestinal diseases, infection, unexplained diarrhea, and antibiotics or probiotics used before recruitment around 1 month were excluded in this study. Subjects were examined during a full night of PSG (SOMNOScreen™ plus PSG®; SOMNOmedics GmbH, Randersacker, Germany) by technologists from 10 p.m. to 8 a.m. at the sleep laboratory. Fasting blood and fecal samples were collected the following morning. The Institutional Review Board of the Second Affiliated Hospital of Fujian Medical University approved this study (IRB No. 2017–78).

2.2 | OSAHS evaluation

All the subjects underwent PSG with a computerized polysomnographic system, simultaneously including electrocardiography, electroencephalography, electromyography, and electrooculography. After one night of examination, apnea-hypopnea index (AHI) was calculated as the total number of episodes of apnea (continuous cessation of airflow for at least 10 s) and hypopnea (reduction in airflow for ≥ 10 s with oxygen desaturation ≤ 4%) by dividing the total sleep by events. According to the diagnostic criteria, as reported previously studies (Heizati et al., 2017; Shao et al., 2018), AHI < 15 events/h was defined as non-OSAHS (control group) and AHI ≥ 15 events/h as OSAHS group.

2.3 | Cytokine analysis

Interleukin (IL)–6 and tumor necrosis factor alpha (TNF-α) were assayed by BD Human Enhanced Sensitivity Cytometric Bead Array Kit (BD Biosciences, New Jersey, USA) as described previously (Kao, Ko,
Magnetic bead isolation was carried out to extract genomic DNA using a TIANamp stool DNA kit (TIANGEN Biotech Co., Ltd., Beijing, China), according to the manufacturer’s instructions. The concentration of extracted DNA was determined by a Nanodrop ND-1000 spectrophotometer (Thermo Electron Corporation, USA), and DNA quality was confirmed using 1.0% agarose gel electrophoresis with 0.5 mg/ml ethidium bromide.

Isolated fecal DNA was used as a template to amplify V3 and V4 hypervariable regions of the bacterial 16S ribosomal RNA gene. V3 and V4 regions were PCR-amplified (forward primer, 5′-ACTCCTACGGGAGGCAGCAG-3′; reverse primer, 5′-GACTACHVGGGTWTCTAAT-3′). The 16S target-specific sequence contained adaptor sequences permitting uniform amplification of a highly complex library ready for downstream next-generation sequencing on Illumina MiSeq (Illumina, USA). Negative DNA extraction controls (lysis buffer and kit reagents only) were amplified and sequenced as contamination controls. The amplicons were normalized, pooled, and sequenced on the Illumina MiSeq platform using a V3 reagent kit with 2 × 300 cycles per sample and with imported and prepared routine data (sample sheet) run in the MiSeq sequence program. After sequencing, Q30 scores were ≥70%, the percentage of clusters passing filter (i.e., cluster PF) was ≥80%, and there were at least 30,000 clean tags. Finally, image analysis and base calling were conducted with MiSeq Control Software.

2.5 Bioinformatic, predictive function, and statistical analyses

Based on the Quantitative Insights into Microbial Ecology bioinformatic pipeline for performing taxonomy assignment by the operational taxonomic unit method, we used data of 113 sequences to analyze the fecal microbiota taxa. We further analyzed between-class analysis by the principal component analysis (PCA) and clustering basis of the genus compositions (Arumugam et al., 2011), utilizing R statistics. We performed other analyses using statistically with SPSS version 19.0 (SPSS Inc., Chicago, Illinois), data were expressed as the mean ± standard deviation (SD). For continuous variables that conformed to a normal distribution, the difference between groups was analyzed by t test or one-way ANOVA. The significant differences within groups were analyzed using ANOVA followed by post-hoc Fisher’s least significant difference (LSD) corrections for multiple comparisons when the analysis of variance was significant. For continuous variables that were not normally distributed, the difference between groups was analyzed using H test. We considered a two-sided p-value of < 0.05 to be statistically significant.

3 RESULTS

3.1 Patient characteristics and enterotype distribution

According to the PCA and clustering of fecal genus compositions for enterotypes class analysis, we enrolled 113 subjects [non-OSAHS (n = 61), OSAHS (n = 52)] were divided according to three enterotypes: Bacteroides [non-OSAHS (n = 41), OSAHS (n = 32)], Ruminococcus [non-OSAHS (n = 6), OSAHS (n = 8)], and Prevotella [non-OSAHS (n = 14), OSAHS (n = 12)] (Figure 1). Ages of Ruminococcus enterotype patients were significantly higher than those of the others enterotype patients (Table 1). BMI of Prevotella enterotype patients were significantly higher than Bacteroides enterotype patients (Table 1). The hip circumference of Prevotella enterotype patients were significantly higher than the others enterotype patients (Table 1).

3.2 Cytokine analysis

There were not significantly different in IL-6 and TNF-α among three enterotypes patients (Figure 2).

3.3 PSG parameter analysis

Comparisons among patients with different enterotypes showed that total sleep arousal index was the lowest in the Prevotella enterotype patients (Table 2).
Using 15 as the AHI cutoff, when AHI ≥ 15, N1 sleep stage, arousal time in REM, and arousal index in REM were the highest in the Prevotella enterotype patients. Contrastingly, sleep latency and arousal time were the lowest in the Prevotella enterotype patients (Table 3).

For Prevotella enterotype patients, N1 sleep stage, N3 sleep stage, arousal index in REM, arousal time in NREM, arousal index in NREM, total sleep arousal times, total sleep arousal index, AHI, apnea-hypopnea times, obstructive apnea index, obstructive apnea times, central apnea index, mixed apnea index, hypopnea index, hypopnea times, longest apnea time, mean apnea-hypopnea duration (MAD), longest hypopnea time, average hypopnea time, oxygen desaturation index, and mean heart rate were significantly elevated in AHI ≥ 15 patients. However, sleep latency, arousal time, lowest oxygen saturation, and average oxygen saturation were significantly decreased in AHI ≥ 15 patients (Table 4).

### 4 | DISCUSSION

OSAHS is a systemic and comprehensive disorder associated with comorbidities, including cardiovascular diseases and metabolic abnormalities. Thus, the IH mechanism alone is insufficient to interpret the complete pathogenesis of OSAHS because OSAHS is also affected by several other aspects, including the CNS causing neuropsychiatric and neurodegenerative disorders (Farré et al., 2018; Gaspar et al., 2017; Lavie, 2015; Rosenzweig et al., 2014). This study shows that arousal-related parameters or sleep stages are significantly disrupted in AHI ≥ 15 patients with Prevotella enterotypes; further analysis, obstructive, central, and mixed apnea indices, and mean heart rate are also significantly elevated in AHI ≥ 15 patients.

Prevotella enterotype is associated with diets high in carbohydrates (fiber) and simple sugars. Bacteroides enterotype is associated with Western-style diets, including consuming high amounts of...
| Enterotypes | Bacteroides | Ruminococcus | Prevotella | post-hoc test |
|-------------|-------------|--------------|------------|--------------|
| enterotype  | (n = 73)    | (n = 14)     | (n = 26)   | p value      |
| Total sleep time (min) | 633.42 ± 58.95 | 648.78 ± 51.83 | 641.11 ± 44.60 | 2.128 | 0.124 | NA | NA | NA |
| N1 sleep stage (min) | 138.56 ± 66.92 | 152.04 ± 82.37 | 171.62 ± 96.22 | 1.819 | 0.167 | NA | NA | NA |
| N1 sleep stage (%) | 36.10 ± 15.90 | 42.19 ± 14.54 | 39.76 ± 17.28 | 1.122 | 0.329 | NA | NA | NA |
| N2 sleep stage (min) | 111.30 ± 60.67 | 85.85 ± 44.25 | 111.94 ± 57.67 | 3.052 | 0.217 | NA | NA | NA |
| N2 sleep stage (%) | 28.10 ± 11.99 | 24.45 ± 9.62 | 25.86 ± 10.48 | 0.814 | 0.446 | NA | NA | NA |
| N3 sleep stage (min) | 71.91 ± 36.85 | 57.71 ± 45.99 | 66.44 ± 41.66 | 0.839 | 0.435 | NA | NA | NA |
| N3 sleep stage (%) | 18.33 ± 8.29 | 15.95 ± 10.23 | 16.25 ± 9.79 | 0.790 | 0.456 | NA | NA | NA |
| Non-rapid eye movement (NREM) (min) | 321.79 ± 87.88 | 295.60 ± 96.74 | 350.01 ± 98.5 | 1.740 | 0.180 | NA | NA | NA |
| NREM (%) | 82.56 ± 10.84 | 82.57 ± 7.62 | 81.87 ± 9.88 | 0.045 | 0.956 | NA | NA | NA |
| Rapid eye movement (REM) (min) | 67.21 ± 43.27 | 67.17 ± 37.26 | 79.63 ± 44.02 | 0.844 | 0.433 | NA | NA | NA |
| REM (%) | 17.43 ± 10.84 | 17.42 ± 7.62 | 18.12 ± 9.88 | 0.046 | 0.955 | NA | NA | NA |
| Sleep efficiency (%) | 70.40 ± 14.99 | 64.62 ± 21.45 | 75.92 ± 18.36 | 2.203 | 0.115 | NA | NA | NA |
| Sleep latency | 31.0 ± 29.96 | 31.7 ± 29.97 | 18.93 ± 20.36 | 4.726 | 0.094 | NA | NA | NA |
| Wake after sleep onset | 129.91 ± 71.69 | 174.76 ± 116.12 | 110.50 ± 98.33 | 2.643 | 0.076 | NA | NA | NA |
| Arousal time (min) | 157.64 ± 78.71 | 202.23 ± 131.03 | 128.14 ± 100.46 | 3.001 | 0.054 | NA | NA | NA |
| Arousal times | 20.35 ± 11.57 | 19.64 ± 12.70 | 14.50 ± 9.36 | 2.631 | 0.077 | NA | NA | NA |
| Arousal index (events/h) | 3.34 ± 2.06 | 3.86 ± 3.19 | 2.30 ± 1.68 | 3.087 | 0.050 | 0.414 | 0.036 | 0.031 |
| Arousal time in REM | 39.93 ± 38.94 | 39.42 ± 34.74 | 52.00 ± 36.13 | 3.870 | 0.144 | NA | NA | NA |
| Arousal index in REM | 32.25 ± 16.44 | 29.52 ± 17.66 | 38.96 ± 16.29 | 2.026 | 0.137 | NA | NA | NA |
| Arousal time in NREM | 210.15 ± 126.03 | 209.57 ± 148.79 | 288.19 ± 226.67 | 1.413 | 0.493 | NA | NA | NA |
| Arousal index in NREM | 38.17 ± 15.54 | 39.98 ± 16.20 | 45.76 ± 26.09 | 0.386 | 0.824 | NA | NA | NA |
| Total sleep arousal times | 250.08 ± 136.58 | 249.00 ± 166.24 | 340.19 ± 249.89 | 1.843 | 0.398 | NA | NA | NA |
| Total sleep arousal index | 38.06 ± 15.18 | 38.75 ± 15.83 | 44.64 ± 24.15 | 0.342 | 0.843 | NA | NA | NA |
| Apnea-hypopnea index (events/h) | 19.63 ± 21.42 | 27.90 ± 22.63 | 27.41 ± 30.96 | 2.285 | 0.319 | NA | NA | NA |
| Apnea-hypopnea times | 132.19 ± 170.66 | 180.50 ± 176.90 | 221.34 ± 278.37 | 1.627 | 0.443 | NA | NA | NA |
| Obstructive apnea index (events/h) | 8.85 ± 15.04 | 10.88 ± 12.44 | 10.62 ± 16.09 | 2.787 | 0.248 | NA | NA | NA |
| Obstructive apnea times | 62.78 ± 120.68 | 71.28 ± 102.99 | 85.26 ± 134.75 | 1.854 | 0.396 | NA | NA | NA |
| Central apnea index (events/h) | 0.46 ± 1.29 | 2.75 ± 8.64 | 1.92 ± 4.04 | 0.694 | 0.707 | NA | NA | NA |
| Central apnea times | 3.39 ± 9.45 | 11.78 ± 31.62 | 17.5 ± 40.21 | 0.778 | 0.678 | NA | NA | NA |

(Continues)
| Enterotype          | Bacteroides | Ruminococcus | Prevotella |
|---------------------|-------------|--------------|------------|
| Post-hoc test       | p value     | p value      | p value    |
| F/χ² value          | B versus R  | B versus P   | R versus P |

| Enterotype          | Mixed apnoea index (events/h) | Mixed apnoea time(s) | Hypopnoea index (events/h) | Hypopnoea time(s) | Mean hypopnoea duration (s) | Longest hypopnoea time (s) | Average hypopnoea time (s) | Oxygen desaturation index (events/h) | Lowest oxygen saturation (%) | Average oxygen saturation (%) | Longest oxygen desaturation (s) | Mean heart rate | Minimum heart rate | Maximum heart rate | Blood pressure elevation index (events/h) | Blood pressure (mmHg) | The highest systolic blood pressure (mmHg) | Average systolic blood pressure (mmHg) |
|---------------------|-----------------------------|----------------------|---------------------------|-------------------|----------------------------|--------------------------|---------------------------|-------------------------------|-----------------------------|-----------------------------|----------------------------|----------------|------------------|----------------|-----------------------------|----------------|-------------------|------------------|
| B                    | 0.59 ± 1.52                 | 1.61 ± 3.80          | 2.88 ± 6.79               | 1.66 ± 6.64       | 1.64 ± 6.64                | 1.64 ± 6.64               | 1.64 ± 6.64                | 1.64 ± 6.64                     | 1.64 ± 6.64                | 1.64 ± 6.64                | 1.64 ± 6.64                | 1.64 ± 6.64 | 1.64 ± 6.64 | 1.64 ± 6.64 | 1.64 ± 6.64                | 1.64 ± 6.64 | 1.64 ± 6.64 | 1.64 ± 6.64 | 1.64 ± 6.64                |
| R                    | 4.56 ± 13.25                | 10.5 ± 27.95         | 25.73 ± 64.80             | 17.68 ± 29.12     | 17.68 ± 29.12              | 17.68 ± 29.12             | 17.68 ± 29.12              | 17.68 ± 29.12                    | 17.68 ± 29.12              | 17.68 ± 29.12              | 17.68 ± 29.12              | 17.68 ± 29.12 | 17.68 ± 29.12 | 17.68 ± 29.12 | 17.68 ± 29.12          | 17.68 ± 29.12 | 17.68 ± 29.12 | 17.68 ± 29.12 | 17.68 ± 29.12          |
| P                    | 6.15 ± 8.95                 | 12.63 ± 7.71         | 11.98 ± 14.29             | 0.03 ± 0.03       | 0.03 ± 0.03                | 0.03 ± 0.03               | 0.03 ± 0.03                | 0.03 ± 0.03                     | 0.03 ± 0.03                | 0.03 ± 0.03                | 0.03 ± 0.03                | 0.03 ± 0.03 | 0.03 ± 0.03 | 0.03 ± 0.03 | 0.03 ± 0.03                | 0.03 ± 0.03 | 0.03 ± 0.03 | 0.03 ± 0.03 | 0.03 ± 0.03                |

Note: Values were calculated as mean ± SD. *Not analyzed.* Because the data do not meet the requirements of variance test, displayed as the Chi-square test corresponding to the H test.
### TABLE 3  Polysomnographic data analysis in three enterotypes of apnoea–hypopnea index ≥ 15 patients

|                     | **Bacteroides** enterotype (n = 32) | **Ruminococcus** enterotype (n = 8) | **Prevotella** enterotype (n = 12) | F/χ² value | p value | post-hoc test | p value | B versus R | B versus P | R versus P |
|---------------------|------------------------------------|------------------------------------|-----------------------------------|------------|---------|--------------|---------|------------|-----------|-----------|
| Total sleep time (min) | 632.59 ± 71.61                     | 663.63 ± 45.48                    | 639.25 ± 41.52                    | 1.803      | 0.176   | NA           | NA      | NA         | NA        | NA        |
| N1 sleep stage (min)  | 162.46 ± 71.21                     | 159.70 ± 98.14                    | 236.23 ± 102.31                   | 3.681      | 0.032   | 0.934        | 0.012   | 0.050      |           |           |
| N1 sleep stage (%)   | 41.93 ± 15.78                      | 41.18 ± 17.37                     | 50.03 ± 16.75                     | 1.199      | 0.310   | NA           | NA      | NA         | NA        | NA        |
| N2 sleep stage (min)  | 111.86 ± 65.07                     | 95.24 ± 48.56                     | 101.92 ± 56.09                    | 0.292      | 0.748   | NA           | NA      | NA         | NA        | NA        |
| N3 sleep stage (min)  | 27.65 ± 11.46                      | 24.23 ± 8.41                      | 22.03 ± 9.76                      | 1.308      | 0.280   | NA           | NA      | NA         | NA        | NA        |
| Non-rapid eye movement (NREM) (min) | 61.95 ± 35.56     | 63.06 ± 55.27                     | 45.71 ± 37.88                     | 0.805      | 0.453   | NA           | NA      | NA         | NA        | NA        |
| REM (%)              | 85.20 ± 10.65                      | 81.94 ± 5.83                      | 81.96 ± 10.05                     | 0.655      | 0.524   | NA           | NA      | NA         | NA        | NA        |
| Rapid eye movement (REM) (min) | 56.65 ± 38.27               | 69.61 ± 33.06                     | 76.83 ± 29.52                     | 1.538      | 0.225   | NA           | NA      | NA         | NA        | NA        |
| Sleep efficiency (%) | 14.80 ± 10.65                      | 18.06 ± 5.83                      | 18.04 ± 10.05                     | 0.655      | 0.524   | NA           | NA      | NA         | NA        | NA        |
| Sleep latency (%)    | 7.06 ± 15.53                       | 68.66 ± 19.05                     | 81.52 ± 16.78                     | 2.227      | 0.119   | NA           | NA      | NA         | NA        | NA        |
| Wake after sleep onset | 131.92 ± 74.80                  | 156.49 ± 119.11                   | 77.79 ± 46.87                     | 2.974      | 0.060   | NA           | NA      | NA         | NA        | NA        |
| Arousal time (min)   | 156.51 ± 76.52                     | 177.55 ± 118.32                   | 84.31 ± 48.77                     | 4.547      | 0.015   | 0.504        | 0.009   | 0.013      |           |           |
| Arousal times (%)    | 19.34 ± 12.06                      | 19.75 ± 14.53                     | 12.50 ± 10.70                     | 1.501      | 0.233   | NA           | NA      | NA         | NA        | NA        |
| Arousal index (events/h) | 3.35 ± 2.52                    | 3.89 ± 4.09                       | 1.89 ± 1.83                       | 1.713      | 0.191   | NA           | NA      | NA         | NA        | NA        |
| Arousal time in REM  | 34.81 ± 29.91                      | 43.00 ± 34.32                     | 66.67 ± 39.80                     | 0.023      | 0.533   | 0.006        | 0.123   |           |           |           |
| Arousal index in REM | 33.37 ± 18.93                      | 34.26 ± 17.70                     | 50.00 ± 13.49                     | 0.011      | 0.898   | 0.008        | 0.057   |           |           |           |
| Arousal time in NREM | 260.28 ± 152.59                    | 262.13 ± 178.51                   | 433.25 ± 262.42                   | 4.190b     | 0.123b  | NA           | NA      | NA         | NA        | NA        |
| Arousal index in NREM | 45.67 ± 17.02                     | 46.20 ± 18.56                     | 63.53 ± 28.16                     | 3.491b     | 0.175b  | NA           | NA      | NA         | NA        | NA        |
| Total sleep arousal times | 295.09 ± 160.44                  | 305.13 ± 194.43                   | 499.92 ± 285.72                   | 4.389b     | 0.111b  | NA           | NA      | NA         | NA        | NA        |
| Total sleep arousal index | 44.99 ± 16.94                    | 44.41 ± 18.55                     | 61.68 ± 25.41                     | 3.919b     | 0.141b  | NA           | NA      | NA         | NA        | NA        |
| Apnea-hypopnea index (events/h) | 36.39 ± 22.86          | 42.04 ± 19.98                     | 52.53 ± 29.78                     | 3.884b     | 0.143b  | NA           | NA      | NA         | NA        | NA        |
| Apnea-hypopnea times | 247.09 ± 204.93                  | 278.88 ± 176.82                   | 430.58 ± 294.38                   | 3.641b     | 0.162b  | NA           | NA      | NA         | NA        | NA        |
| Obstructive apnea index (events/h) | 18.03 ± 19.14                | 14.43 ± 15.52                     | 21.38 ± 18.74                     | 0.560b     | 0.756b  | NA           | NA      | NA         | NA        | NA        |
| Obstructive apnea times | 129.47 ± 159.54                 | 99.88 ± 129.97                    | 173.25 ± 159.52                   | 1.534b     | 0.465b  | NA           | NA      | NA         | NA        | NA        |
| Central apnea index (events/h) | 0.98 ± 1.83                    | 4.81 ± 11.28                      | 3.83 ± 5.40                       | 0.731b     | 0.694b  | NA           | NA      | NA         | NA        | NA        |
| Central apnea times | 7.09 ± 13.44                     | 20.63 ± 40.61                     | 35.50 ± 54.65                     | 0.578b     | 0.749b  | NA           | NA      | NA         | NA        | NA        |

(Continues)
| Table 3 (Continued) |
|---------------------|
| **Bacteroides** enterotype | **Ruminococcus** enterotype | **Prevotella** enterotype | \( F/\chi^2 \) value | \( p \) value | post-hoc test |
| \( n = 32 \) | \( n = 8 \) | \( n = 12 \) | | | \( B \) versus \( R \) | \( B \) versus \( P \) | \( R \) versus \( P \) |
| Mixed apnea index (events/h) | 1.31 ± 2.10 | 2.78 ± 4.81 | 6.19 ± 9.08 | 1.852b | 0.396b | NA | NA | NA |
| Mixed apnea times | 10.13 ± 18.71 | 18.13 ± 36.00 | 55.33 ± 88.13 | 2.091b | 0.351b | NA | NA | NA |
| Hypopnea index (events/h) | 16.08 ± 9.56 | 19.99 ± 20.79 | 21.17 ± 16.88 | 0.734 | 0.485 | NA | NA | NA |
| Hypopnea times | 100.41 ± 57.37 | 140.25 ± 163.59 | 166.50 ± 155.08 | 0.977b | 0.614b | NA | NA | NA |
| Longest apnea time (s) | 50.31 ± 19.59 | 47.63 ± 29.34 | 69.08 ± 38.55 | 2.494 | 0.093 | NA | NA | NA |
| Mean apnea-hypopnea duration (s) | 23.20 ± 6.35 | 20.30 ± 6.90 | 26.97 ± 7.53 | 2.531 | 0.090 | NA | NA | NA |
| Longest hypopnea time (s) | 82.69 ± 28.53 | 70.25 ± 25.97 | 99.75 ± 24.15 | 3.044 | 0.057 | NA | NA | NA |
| Average hypopnea time (s) | 31.29 ± 6.58 | 28.53 ± 6.55 | 35.74 ± 8.24 | 2.871 | 0.066 | NA | NA | NA |
| Oxygen desaturation index (events/h) | 34.23 ± 22.94 | 38.98 ± 22.58 | 49.73 ± 29.24 | 1.758 | 0.183 | NA | NA | NA |
| Lowest oxygen saturation (%) | 76.31 ± 9.20 | 76.00 ± 10.01 | 74.83 ± 12.04 | 0.095 | 0.909 | NA | NA | NA |
| Average oxygen saturation (%) | 93.31 ± 2.32 | 93.13 ± 4.09 | 92.50 ± 2.81 | 1.111b | 0.574b | NA | NA | NA |
| Longest oxygen desaturation (s) | 113.18 ± 37.43 | 103.39 ± 23.54 | 92.93 ± 26.57 | 1.646 | 0.203 | NA | NA | NA |
| Mean heart rate | 66.56 ± 10.38 | 67.25 ± 6.67 | 67.83 ± 10.83 | 0.074 | 0.929 | NA | NA | NA |
| Arrhythmia index (events/h) | 5.29 ± 13.97 | 65.06 ± 177.85 | 3.82 ± 5.03 | 0.784b | 0.676b | NA | NA | NA |
| Maximum heart rate | 99.09 ± 14.79 | 99.75 ± 15.64 | 103.08 ± 18.70 | 0.278 | 0.758 | NA | NA | NA |
| Minimum heart rate | 51.88 ± 7.07 | 54.50 ± 4.44 | 53.50 ± 6.56 | 0.626 | 0.539 | NA | NA | NA |
| Blood pressure elevation index (events/h) | 20.91 ± 18.96 | 20.44 ± 18.45 | 26.09 ± 27.79 | 0.288 | 0.751 | NA | NA | NA |
| The highest systolic blood pressure (mmHg) | 172.97 ± 35.54 | 180.75 ± 38.26 | 163.25 ± 62.49 | 0.414 | 0.663 | NA | NA | NA |
| Average systolic blood pressure (mmHg) | 130.44 ± 22.64 | 138.50 ± 22.91 | 117.58 ± 41.10 | 1.508 | 0.231 | NA | NA | NA |
| Average diastolic blood pressure (mmHg) | 87.28 ± 13.38 | 88.00 ± 9.94 | 84.25 ± 29.45 | 0.150 | 0.861 | NA | NA | NA |

**Note.** Values were calculated as mean ± SD.

*Not analyzed. bBecause the data do not meet the requirements of variance test, displayed as the Chi-square test corresponding to the H test.
| TABLE 4  Polysomnographic data analysis in Prevotella enterotype subjects |
|-----------------------------|-----------------------------|
|                            | AHI <15                     | AHI ≥ 15                     |
| Total sleep time (min)     | 403.04 ± 118.21              | 460.69 ± 117.35              |
| N1 sleep stage (min)       | 116.25 ± 42.34               | 236.23 ± 102.31**            |
| N1 sleep stage (%)         | 30.96 ± 12.49                | 50.03 ± 16.75**              |
| N2 sleep stage (min)       | 120.54 ± 59.68               | 101.92 ± 56.09               |
| N2 sleep stage (%)         | 29.15 ± 10.26                | 22.03 ± 9.76                 |
| N3 sleep stage (min)       | 84.21 ± 37.23                | 45.71 ± 37.88*               |
| N3 sleep stage (%)         | 21.70 ± 7.83                 | 9.90 ± 7.97**                |
| Non-rapid eye movement (NREM) (min) | 321.00 ± 78.85                 | 383.86 ± 111.29              |
| NREM (%)                   | 81.80 ± 10.11                | 81.96 ± 10.05                |
| Rapid eye movement (REM) (min) | 82.04 ± 54.54                 | 76.83 ± 29.52                |
| REM (%)                    | 18.20 ± 10.11                | 18.04 ± 10.05                |
| Sleep efficiency (%)       | 71.13 ± 18.87                | 81.52 ± 16.78                |
| Sleep latency              | 28.36 ± 23.75                | 7.93 ± 5.48**                |
| Wake after sleep onset     | 138.54 ± 122.07              | 77.79 ± 46.87                |
| Arousal time (min)         | 165.71 ± 118.75              | 84.31 ± 48.77**              |
| Arousal times              | 16.21 ± 8.06                 | 12.50 ± 10.70                |
| Arousal index (events/h)   | 2.66 ± 1.52                  | 1.89 ± 1.83                  |
| Arousal time in REM        | 39.43 ± 28.30                | 66.67 ± 39.80                |
| Arousal index in REM       | 29.50 ± 12.13                | 50.00 ± 13.49***             |
| Arousal time in NREM       | 163.86 ± 66.82               | 433.25 ± 262.42**            |
| Arousal index in NREM      | 30.54 ± 9.82                 | 63.53 ± 28.16**              |
| Total sleep arousal times  | 203.29 ± 85.31               | 499.92 ± 285.72**            |
| Total sleep arousal index  | 30.04 ± 8.81                 | 61.68 ± 25.41**              |
| Apnea-hypopnea index (events/h) | 5.88 ± 3.43                    | 52.53 ± 29.78***             |
| Apnea-hypopnea times       | 42.00 ± 25.31                | 430.58 ± 294.38**            |
| Obstructive apnea index (events/h) | 1.41 ± 1.65                   | 21.38 ± 18.74**              |
| Obstructive apnea times    | 9.86 ± 10.79                 | 173.25 ± 159.52**            |
| Central apnea index (events/h) | 0.30 ± 0.77                    | 3.83 ± 5.40*                 |
| Central apnea times        | 2.07 ± 5.14                  | 35.50 ± 54.65                |
| Mixed apnea index (events/h) | 0.05 ± 0.09                 | 6.19 ± 9.08*                |
| Mixed apnea times          | 0.36 ± 0.63                  | 55.33 ± 88.13                |
| Hypopnea index (events/h)  | 4.11 ± 2.65                  | 21.17 ± 16.88**              |
| Hypopnea times             | 29.71 ± 21.00                | 166.50 ± 155.08**            |
| Longest apnea time (s)     | 24.86 ± 24.59                | 69.08 ± 38.55**              |
| Mean apnea-hypopnea duration (s) | 14.06 ± 7.29                 | 26.97 ± 7.53***             |
| Longest hypopnea time (s)  | 60.29 ± 28.51                | 99.75 ± 24.15**              |
| Average hypopnea time (s)  | 27.91 ± 6.86                 | 35.74 ± 8.24*                |
| Oxygen desaturation index (events/h) | 5.48 ± 3.66                 | 49.73 ± 29.24***            |
| Lowest oxygen saturation (%) | 88.57 ± 3.34               | 74.83 ± 12.04***            |
| Average oxygen saturation (%) | 95.00 ± 1.79                 | 92.50 ± 2.81**              |
| Longest oxygen desaturation (s) | 84.23 ± 33.17               | 92.93 ± 26.57               |
| Mean heart rate            | 62.00 ± 9.08                 | 67.83 ± 10.83*              |
| Arrhythmia index (events/h) | 2.02 ± 2.09                  | 3.82 ± 5.03                  |
| Maximum heart rate         | 94.00 ± 4.60                 | 103.08 ± 18.70              |
| Minimum heart rate         | 51.67 ± 6.12                 | 53.50 ± 6.56                |

(Continues)
protein and fat, whereas *Ruminococcus* species enterotype is linked to nondigestible carbohydrates (Conlon & Bird, 2015). Despite the fact that the *Bacteroides* predominant enterotype seems to be more common in IBD patients, the *Prevotella* enterotype is more representative in healthy subjects (Costea et al., 2018; Knights et al., 2014). Our findings show that *Bacteroides* enterotype patients are not susceptible to OSAHS, in contrast to the susceptibility of *Prevotella* enterotype patients.

IH-exposed mice mimic OSAHS, causing profound alterations in gut microbiota. Hypoxia/re-oxygenation is the most pronounced (Moreno-Indias et al., 2015), inducing an alteration in intestinal epithelial barrier markers and increasing intestinal permeability, leading to local and systemic inflammatory responses and consequent multi-organ morbidities (Barceló et al., 2016; Grootjans et al., 2010). However, only *Bacteroides* and *Prevotella* enterotypes can be classified in the rodent model, IH-exposed mice classify as the *Prevotella* enterotype (Moreno-Indias et al., 2015), which is similar to our particularly OSAHS patients. It has further been shown that IH leads to gut microbiota alteration and accompanying endotoxin production (Maes, Kubera, & Leunis, 2008). It is that IH model creates an anoxic environment in the intestine, which is beneficial for obligate anerobic bacterial growth, endogenous LPS production from gram-negative bacteria, and triggering inflammation. Notably, *Prevotella* is a genus of gram-negative anerobic bacteria, and it has a tendency to alter intestinal permeability (Moreno-Indias et al., 2015, 2016). Although this evidence only reveals the IH contribution to the pathogenesis, we also speculated that SF is another principal contributor (Poroyko et al., 2016). SF-induced mice manifest inflammation and enhanced production of endotoxins produced by gut microbiota, too (Poroyko et al., 2016). Taken together, LPS may play a crucial role in driving systemic inflammation, it has been shown in IH and SF modeling OSAHS models (Moreno-Indias et al., 2015, 2016; Poroyko et al., 2016). Moreover, in middle-aged non-obese males with OSAHS, disruption of the intestinal barrier, and concurrent increased serum d-lactate levels possibly contribute to intestinal hyperpermeability and are significantly positively associated with pro-inflammatory IL-1β, IL-6, and TNF-α cytokines in serum (Heizati et al., 2017) in which TNF-α elevation in *Prevotella* enterotype subjects is similar with our results, but it did not reach statistically significant differences.

*Prevotella* enterotype patients with AHI ≥ 15 in our results, suggesting that LPS production triggers downstream signaling pathways, leading to the subsequent release of pro-inflammatory cytokines (Tobias, Soldau, & Ulevitch, 1989). Furthermore, the elevation of LPS-binding protein is also verified in OSAHS mimicking rodent models (Poroyko et al., 2016) and patients (Heizati et al., 2017), particularly regarding in the higher d-lactate level of OSAHS patients. Inflammatory mediators can be produced by peripheral and central cells. Peripheral inflammatory mediators may invade the CNS by crossing the blood–brain barrier, affecting behaviors and causing metabolic problems and psychiatric disorders (Ko & Liu, 2016). Here, our data suggest that the gut microbiota might impact the brain in OSAHS patients by modulating inflammatory responses.

Additionally, we should mention that the *Prevotella* enterotype is linked to diets rich in simple sugars. Simple carbohydrate consumption has been hypothesized to be related to elevated BP values and obesity (Orlando, Cazzaniga, Giussani, Palestini, & Genovesi, 2018), as showed in our data. *Prevotella* enterotype patients had a higher BMI and hip circumference than *Bacterioides* enterotype patients. Monosaccharide intake induces inflammation in epithelial cells and contributes to hypertension (Orlando et al., 2018), linking to LPS production, which can stimulate systemic inflammatory cascades (Moreno-Indias et al., 2015). Inflammation mediates the pathogenesis of many physiological dysfunctions, such as metabolic syndrome and mental dysfunction (Ko & Liu, 2016), and thus might ultimately result in OSAHS-related metabolic comorbidities. Although *Ruminococcus* is associated with resistant starch, host health benefits from short chain fatty acids that have been demonstrated to regulate immune inflammatory responses (Macfarlane & Macfarlane, 2012). The enriched bacteria *Ruminococcus* spp. and *Sutterella* spp. are found in psychiatric patients (Wang et al., 2013). The abovementioned literature supports the hypothesis that microbiota disruption influences the pathophysiological process of OSAHS might be through a microbiota–gut–brain axis.

Despite OSAHS is one of the most common sleep apnea syndromes (SAS), other types are mixed sleep apnea (MSA) and central sleep apnea (CSA). The prevalence of OSAHS, complex SAS (CompSAS), and central SAS are 84.0%, 15.0%, and 0.4%, respectively (Morgenthaler, Kagramanov, Hanak, & Decker, 2006). MSA generally describes the mixture of both obstructive and central apnea events during diagnostic sleep, although many central apnea indices occurrence is also identified as MSA, which is sometimes
referred to as CompSAS (Khan & Franco, 2014). Whereas CompSAS is a form of CAS wherein the persistence or emergence of central apneas or hypopneas has disappeared with CPAP, patients have predominately obstructive or mixed apneas occurring at ≥ 5 events/h (Gay, 2008). Additionally, reportedly, there is a high prevalence of hypertension and heart disease in patients with CompSAS (Westhoff, Arzt, & Litterst, 2012). In our data, all of apnea indices were significantly increased in Prevotella enterotype patients with AHI ≥ 15. Thus, abnormalities in electrocardiography, electroencephalography, electromyography, and electro-oculography results should be more concern.

Both IH and SF have been demonstrated to independently affect similar CNS regions in animal research (Rosenzweig et al., 2014). The N1 sleep stage is associated with the transition from wakefulness to other sleep stages or the following arousal during sleep. A higher N1 percentage might mean more events of wakefulness and/or arousal, SF (episodic arousal from sleep), and sympathetic overactivity during sleep (Shao et al., 2018). REM sleep dysregulation significantly contributes to cognitive distortions and dysfunctions that rely on emotion and memory functions are also affected (Palagini et al., 2013). Moreover, the effects of sleep deprivation on cognition have been investigated (Killgore, 2010). Thus, OSAHS patients have been found to have neurocognitive and emotional disorders, suggesting the modulation of various neurotransmitters during the sleep period (Rosenzweig et al., 2014). Recently, a multicenter randomized controlled trial has been initiated evaluating the extent to which CPAP treatment improves neurocognitive dysfunction in OSAHS patients and examining the role of gut microbiota in this change (Xu et al., 2017). Preliminary results suggest the viability of the hypothesis that microbiota modulate central nervous functions in OSAHS patients.

Although the neural mechanisms underlying SAS-induced brain injury have not been completely elucidated, repeated arousals enable the characterization of the different stages of sleep. In this study, the N1 sleep stage, MAD, and arousal index were increased in Prevotella enterotype patients. BP was not significantly different among the three enterotype AHI ≥ 15 patient groups, but mean diastolic pressure during sleep was > 80 mmHg, which was similar to that observed in a previous study (Shao et al., 2018). MAD can act as an indicator of the levels of sleep parameters and blood oxygenation for the evaluation of severe OSAHS patients (Zhan, Fang, Wu, Pinto, & Wei, 2018). When MAD is elevated, sleep apnea appears to be more likely to cause respiratory arousal and might impair sleep stability, resulting in SF. This outcome might then be that the transition of the N2 sleep stage (the longest stage of sleep) to the N3 sleep stage is a vulnerable period, which is interrupted in OSAHS patients, and the overall sleep pattern becomes light sleep (Zhan et al., 2018). Additionally, chronic SF induction elevates fat mass, alters fecal microbiota, promotes increased gut permeability, leads to systemic and adipose tissue inflammatory changes, and accompanies metabolic dysfunction (Poroyko et al., 2016). These symptoms are known to be associated with OSAHS-related metabolic comorbidities, implying that the microbiota–gut–brain axis has a biaxial effect on the development of OSAHS pathology.

Contrastingly, evidence has shown that N1, N3, and REM sleep stages decrease and the N2 sleep stage increases in OSAHS patients (Rosenzweig et al., 2014). However, a higher N1 percentage, a longer MAD, and a shortened REM sleep stage were revealed in AHI ≥ 15 patients with OSAHS-induced hypertension (Shao et al., 2018; Zhan et al., 2018). Our findings reveal that BP plays a vital role, particularly for SAS, where BP is comprehensively regulated by the peripheral and central systems. Hence, future studies should re-examine these questions in subgroups of hypertensive and normotensive OSAHS patients to evaluate their general applicability.

In summary, this study initiates a new approach to the study of sleep apnea through a combination of polysomnographic measurements with analysis of enterotypes. Obstructive, central, and mixed apnea indices, N1 and N3 sleep stages, MAD, arousal indices, and mean heart rate were all prominently increased in AHI ≥ 15 patients with the Prevotella enterotype. Our results raise the possible association that the microbiota–gut–brain axis operates bidirectionally, with significant impact on the pathogenesis of OSAHS including functions of the gut and brain that eventually contribute to multiple end-organ morbidities.

ACKNOWLEDGMENTS

We thank all the participants and their families who took part in this study. The authors appreciate the assistance provided by Huan Wu (G-BIO Biotech, Inc., Hangzhou, China) for performing the bioinformatic analysis. The authors would also like to thank the Fujian Provincial Health and Family Planning Commission, China, under contract No. 2018-CX-36; Fujian Province Science and Technology Project, China, under contract No. 2018J01290 and No. 2015J01445; and Quanzhou Science and Technology Project, China, under contract No. 2018Z107, No. 2018N003S, No. 2017Z016, and No.2013Z55; and contract No. 2014JQNC20 for Young people training project from Fujian Province Health System. This article was also subsidized by Strait Exchanges Postdoctoral Funding Schemes of Fujian Province, China, and academic funding of the Second Affiliated Hospital of Fujian Medical University (serial No. BSH001).

CONTRIBUTORS

Conceptualization: C.Y.K., H.P.Z., and Y.M.Z.; Investigation: C.Y.K., A.K.H., J.M.F., L.M.H., J.H.Y., and H.Z.S.; Data curation and Visualization: C.Y.K., A.K.H., J.M.F., F.R.Y., H.P.Z., and Y.M.Z.; Writing-Review and Editing: C.Y.K., H.P.Z., and Y.M.Z.

DECLARATIONS OF CONFLICT OF INTEREST

The authors declare that they have no financial and personal relationships with others that may inappropriately influence the results and interpretation in this manuscript.
pla plays a role in the inflammatory pathophysiology of depression. Neuroendocrinology Letters, 29(1), 117–124. https://doi.org/10.3086/npendmet0726

Moreno-Indias, I., Torres, M., Montserrat, J. M., Sanchez-Alcohalo, L., Cardona, F., Tinahones, F. J., ... Farré, R. (2015). Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. European Respiratory Journal, 45(4), 1055–1065. https://doi.org/10.1183/09031936.00184314

Moreno-Indias, I., Torres, M., Sanchez-Alcohalo, L., Cardona, F., Almendros, I., Gozal, D., ... Farré, R. (2016). Normoxic recovery mimicking treatment of sleep apnea does not reverse intermittent hypoxia-induced bacterial dysbiosis and low-grade endotoxemia in mice. Sleep, 39(10), 1891–1897. https://doi.org/10.5665/sleep.6176

Morgenthaler, T. I., Kagramanov, V., Hanak, V., & Deckr, P. A. (2006). Complex sleep apnea syndrome: Is it a unique clinical syndrome? Sleep, 29, 1203–1209. https://doi.org/10.1093/sleep/29.9.1203

Orlando, A., Cazzaniga, E., Giussani, M., Palestini, P., & Genovesi, S. (2018). Hypertension in children: Role of obesity, simple carbohydrates, and uric acid. Frontiers in Public Health, 6, 129. https://doi.org/10.3389/fpubh.2018.00129

Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A., & Riemann, D. (2013). REM sleep disorganization in depression: State of the art. Sleep Medicine Reviews, 17(5), 377–390. https://doi.org/10.1016/j.smrv.2012.11.001

Poroyko, V. A., Carreras, A., Khalyfa, A., Khalyfa, A. A., Leone, V., Peris, E., ... Gozal, D. (2016). Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice. Scientific Reports, 6, 35405. https://doi.org/10.1038/srep35405

Rosenzweig, I., Williams, S. C., & Morrell, M. J. (2013). Cross Talk opposing view: The intermittent hypoxia attending severe obstructive sleep apnoea does not lead to alterations in brain structure and function. The Journal of Physiology, 591(2), 383–385. https://doi.org/10.1113/jphysiol.2012.241224

Rosenzweig, I., Williams, S. C., & Morrell, M. J. (2014). The impact of sleep and hypoxia on the brain: Potential mechanisms for the effects of obstructive sleep apnea. Current Opinion in Pulmonary Medicine, 20(6), 565–571. https://doi.org/10.1097/MCP.0000000000000099

Shao, L., Heizhati, M., Yao, X., Wang, Y., Abulikemu, S., Zhang, D., ... Li, N. (2018). Influences of obstructive sleep apnea on blood pressure variability might not be limited only nocturnally in middle-aged hypertensive males. Sleep Breath, 22(2), 377–384. https://doi.org/10.1007/s11325-017-1571-9

Sherwin, E., Sandhu, K. V., Dinan, T. G., & Cryan, J. F. (2016). May the force be with you: The light and dark sides of the microbiota-gut-brain axis in neuropsychiatry. CNS Drugs, 30(11), 1019–1041. https://doi.org/10.1007/s40263-016-0370-3

Singh, R. K., Chang, H.-W., Yan, D. I., Lee, K. M., Ucmak, D., Wong, K., ... Liao, W. (2017). Influence of diet on the gut microbiome and implications for human health. Journal of Translational Medicine, 15(1), 73. https://doi.org/10.1186/s12967-017-1517-y

Tobias, P. S., Soldau, K., & Ulevitch, R. J. (1989). Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. Journal of Biological Chemistry, 264(18), 10867–10871

Wang, L., Christophersen, C. T., Sorich, M. J., Gerber, J. P., Angley, M. T., & Conlon, M. A. (2013). Increased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorder. Molecular Autism, 4(1), 42. https://doi.org/10.1186/2040-2392-4-42

Westhoff, M., Arzt, M., & Litterst, P. (2012). Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure. Sleep Breath, 16(1), 71–78. https://doi.org/10.1007/s11325-011-0486-0

Xu, H., Wang, H., Guan, J., Yi, H., Qian, Y., Zou, J., ... Yin, S. (2017). Effects of continuous positive airway pressure on neurocognitive
architecture and function in patients with obstructive sleep apnoea: Study protocol for a multicentre randomised controlled trial. *British Medical Journal Open*, 7(5), e014932. https://doi.org/10.1136/bmjopen-2016-014932

Zhan, X., Fang, F., Wu, C., Pinto, J. M., & Wei, Y. (2018). A retrospective study to compare the use of the mean apnea-hypopnea duration and the apnea-hypopnea index with blood oxygenation and sleep patterns in patients with obstructive sleep apnea diagnosed by polysomnography. *Medical Science Monitor*, 4, 1887–1893. https://doi.org/10.12659/MSM.909219

How to cite this article: Ko C-Y, Fan J-M, Hu A-K, et al. Disruption of sleep architecture in Prevotella enterotype of patients with obstructive sleep apnea-hypopnea syndrome. *Brain Behav*. 2019;9:e01287. https://doi.org/10.1002/brb3.1287